Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368926 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01368926 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 42 participants.
The verdict
NCT01368926, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This double-blind, randomized, placebo-controlled, 2-Part study will evaluate the pharmacokinetics and safety of RO4917523 in healthy Japanese and Caucasian volunteers. In Part 1, healthy Japanese volunteers will be randomized to receive 2 oral doses of either RO4917523 or placebo, with a washout period of 21 days between dosing. In Part 2, healthy Japanese and Caucasian volunteers will be randomized in cohorts to receive either RO4917523 or placebo orally daily for 14 days.
Interventions
- DRUG placebo
- DRUG RO4917523
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01368926
The ClinicalTrials.gov registry entry for NCT01368926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01368926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01368926 about?
NCT01368926 is a clinical study titled "A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects". This double-blind, randomized, placebo-controlled, 2-Part study will evaluate the pharmacokinetics and safety of RO4917523 in healthy Japanese and Caucasian volunteers. In Part 1, healthy Japanese volunteers will be randomized to receive 2 oral doses of either RO4917523 or placebo, with a washout pe...
What is the current status of trial NCT01368926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2011-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01368926?
The interventions under investigation include: placebo (DRUG), RO4917523 (DRUG).
Who is sponsoring clinical trial NCT01368926?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.